Russian Heart Failure Journal 2011year Efficiency and acceptability of ramipril for patients with hyperpiesia and chronic heart failure


To access this material please log in or register

Register Authorize
2011/

Efficiency and acceptability of ramipril for patients with hyperpiesia and chronic heart failure

Napalkov D. A., Chilenko A. V.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: arterial hypertension, safety, ramipril, CHF, efficiency

DOI: 10.18087/ rhfj.2011.5.1595

Relevancy. A number of large placebos – controlled randomized studies revealed the efficiency and safety of ramipril therapy for the patients with high cardiovascular risk. Objective. Study of the antihypertensive efficiency and acceptability of ramipril for the hyperpiesis and CHF patients. Materials and methods. The study included 30 hyperpiesis and CHF patients who were prescribed ramipril (piramil), after withdrawal of angiotensine transforming enzyme inhibitors; average dose was 7.7 mg / day. Observation time was 6 months. Patients checkup included blood pressure control, ECG, echocardiography, clinical and biochemical blood tests. Results. As a result systolic blood pressure decreased from 153±24.5 to 128±8.3 mm (p=0.03), and diastolic blood pressure – from 94±12.0 to 80±2.5 mm (p=0.006); uric acid content in blood decreased as well. The therapy showed the decrease of relative expected 5-year death rate according Seattle model for the evaluation of the cardiovascular risk for the CHF patients, the average value was from 15.2 to 13.8 % and expected life time increased from 15 to 15.6 years. In the course of ramipril therapy only one patient had (3.3 %) a short cough and that did not lead to the medicine withdrawal.
  1. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения сердечной недостаточности. – М.: Materia Medica, 2000. – 266с.
  2. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  3. Никифоров В. С., Свистов А. С. Современные направления применения ингибиторов ангиотензин-превращающего фермента в клиниче­ской практике. ФАРМиндекс- Практик. 2005;7:21–31.
Napalkov D. A., Chilenko A. V. Efficiency and acceptability of ramipril for patients with hyperpiesia and chronic heart failure. Russian Heart Failure Journal. 2011;12(5):267-269.

To access this material please log in or register

Register Authorize
Ru En